IP Library › Granted Patent US 12,065,450
Granted Patent B2
US 12,065,450 · App. 17/809,493 · Granted Aug 20, 2024

Compounds and the use thereof in metathesis reactions

Inventors: Florian Toth (Budapest, HU); Georg Frater (Horw, CH); Levente Ondi (Budapest, HU)
Assignee: Verbio SE
C07F11/00B01J31/2265C07C6/04C07C67/333C07C67/475C07D321/00B01J2231/543B01J2531/64B01J2531/66C07C2531/22C07C2601/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,065,450
App. No.
17/809,493
Granted
Aug 20, 2024
Kind
B2
Abstract

The disclosure provides Group 6 complexes, which, in some embodiments, are useful for catalyzing olefin metathesis reactions. In some embodiments, the compounds are compounds of the following formula: wherein: M is a Group 6 metal atom; X is an oxygen atom, ═N—R 5 , ═N—N(R 5 )(R 5′ ) or ═N—O—R 5 , R 5 and R 5′ independently being various substituents, such as aryl or heteroaryl, each optionally substituted; n is 0 or 1; R z is a neutral ligand; R 1 is hydrogen or an organic substituent; R 2 is an aryl or heteroaryl group, each optionally substituted; R 3 is an anionic ligand; and R 4 is an anionic ligand, such as a pyrrolide, a pyrazolide, an imidazolide, an indolide, an azaindolide, or an indazolide, each optionally substituted.

Claims (42)

1. A compound of Formula (II)

wherein:

M is a molybdenum atom or a tungsten atom;

R 101 is phenyl, alkyl, or cycloalkyl, each of which is optionally substituted;

R 102 is pyrrolyl or indolyl, each of which is optionally substituted;

R 103 is 2,6-diphenylphenyl or 4-bromo-2,3,5,6-tetraphenylphenyl, or

R 103 is:

wherein “iPr” refers to isopropyl, and “OTBDMS” refers to tert-butyldimethylsilyloxy;

R 104 is a hydrogen atom;

R 105 is —O—(C 1-6 alkyl) or —CH 2 —O—(C 1-6 alkyl); and

R 106 and R 107 are independently a hydrogen atom, C 1-6 alkyl, C 1-6 alkoxy, or a halogen atom.

2. The compound of claim 1 , wherein R 101 is phenyl, 2,6-dichlorophenyl, 2,6-dimethylphenyl, 2,6-diisopropylphenyl, 2-trifluoromethylphenyl, pentafluorophenyl, tert-butyl, or 1-adamantyl.

3. The compound of claim 1 , wherein R 102 is pyrrol-1-yl, 2,5-dimethylpyrrol-1-yl, 2,5-diphenylpyrrol-1-yl, or indol-1-yl.

4. The compound of claim 1 , wherein R 105 is methyloxy, ethyloxy, or isopropyloxy.

5. The compound of claim 1 , wherein R 106 and R 107 are independently a hydrogen atom, methyl, a halogen atom, or methyloxy.

6. A method for carrying out a metathesis reaction, the method comprising:

providing a first compound having one or more carbon-carbon double bonds; and

reacting the first compound via a metathesis reaction in the presence of a compound of claim 1 .

7. The method of claim 6 , wherein the first compound has two or more carbon-carbon double bonds.

8. The method of claim 7 , wherein the metathesis reaction is a ring-closing metathesis reaction between two of the two or more carbon-carbon double bonds of the first compound.

9. A method of carrying out a metathesis reaction, the method comprising:

providing a first compound having one or more carbon-carbon double bonds and a second compound having one or more carbon-carbon double bonds; and

reacting the first compound and the second compound via a metathesis reaction in the presence of a compound of claim 1 .

10. The method of claim 9 , wherein the first compound and the second compound are the same compound.

11. The method of claim 9 , wherein the first compound and the second compound are not the same.

12. The method of claim 11 , wherein the first compound is an internal olefin.

13. The method of claim 12 , wherein the second compound is a short-chain alkene.

14. The method of claim 13 , wherein the short-chain alkene is ethylene.

15. The method of claim 10 wherein the first compound is an unsaturated ester.

16. The method of claim 14 , wherein the first compound is an unsaturated ester.

17. The compound of claim 1 , wherein M is a tungsten atom.

18. The compound of claim 1 , wherein:

M is a tungsten atom;

R 101 is 2,6-dichlorophenyl;

R 102 is 2,5-dimethylpyrrol-1-yl;

R 103 is:

wherein “OTBDMS” refers to tert-butyldimethylsilyloxy;

R 104 is hydrogen;

R 105 is methyloxy;

R 106 is hydrogen; and

R 107 is hydrogen.

19. The compound of claim 1 , comprising a neutral ligand.

Assignments (4)
CHANGE OF NAME Recorded Jan 26, 2024
From: VERBIO VEREINIGTE BIOENERGIE AG
To: VERBIO SE
Reel/Frame 066376/0063 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY PREVIOUSLY RECORDED AT REEL: 060341 FRAME: 0578. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jul 20, 2022
From: XIMO AG
To: VERBIO VEREINIGTE BIOENERGIE AG
Reel/Frame 060767/0906 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2022
From: TOTH, FLORIAN; FRATER, GEORG; ONDI, LEVENTE
To: XIMO AG
Reel/Frame 060341/0506 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2022
From: XIMO AG
To: VEREINIGTE BIOENERGIE AG
Reel/Frame 060341/0578 →
Priority Claims (1)
GB 1406591 · Apr 11, 2014 · national
Continuity (5)
Continuation 16988199 · Aug 7, 2020
Continuation 16167250 · Oct 22, 2018
Continuation 15303089
Provisional Application 62007987 · Jun 5, 2014
Related Publication 20230013959A1 · Jan 19, 2023